For years, healthcare operators have heard the same directive: move from volume to value. The future of healthcare reimbursement models, however, will not be settled by a slogan or a single CMS demonstration. It will be determined by a harder question: which organizations can accept financial accountability for outcomes without losing control of cost, access, and clinical quality?
That question has particular force in senior living, skilled nursing, home health, hospice, and post-acute care. These sectors sit at the intersection of Medicare spending growth, workforce scarcity, hospital capacity constraints, and a rapidly aging population. Policymakers need care delivered in lower-cost settings. Payors need proof that lower cost does not mean lower quality. Operators need reimbursement that reflects clinical complexity rather than rewarding the fastest discharge or the narrowest definition of care.
The next reimbursement era will be more selective, more data-intensive, and less forgiving of organizations that cannot demonstrate their value.
CMS Medicare Innovation and Payment Models
The Centers for Medicare & Medicaid Services (CMS) Innovation Center (CMMI) Overview | CMS has announced more than 100 alternative payment and service delivery models and launched over 40 distinct payment models since its creation. These initiatives are active or time-limited experiments designed to test different approaches to care delivery, reimbursement, and provider accountability. https://youtu.be/juE4Q8AHBAk?si=8kNcEvGogIhakZLa
CMS Innovation Center Model Focus Areas
- Accountable care: Supports coordinated provider networks that share financial accountability for quality and cost outcomes.
- Episode-based payment: Focuses on defined clinical episodes or procedures, such as joint replacements.
- Primary care transformation: Strengthens primary care delivery through models such as advanced primary care practices and medical homes.
- Medicaid and CHIP: Tests state-level and targeted models for children, low-income populations, and other Medicaid or CHIP beneficiaries.
CMS does not maintain a separate Innovation Center category dedicated solely to post-acute care (PAC). Instead, post-acute reimbursement is generally incorporated into broader episode-based payment initiatives, including the Bundled Payments for Care Improvement (BPCI) initiative, Comprehensive Care for Joint Replacement (CJR), and the Transforming Episode Accountability Model (TEAM). Historically, the major pilot structures that directly targeted or substantially incorporated post-acute episodes include BPCI Models 2 and 3, BPCI Advanced, CJR, and TEAM.
Episode Models Involving Post-Acute Care
- BPCI Classic: Tested four models, including Model 2, which covered acute and post-acute care, and Model 3, which focused specifically on post-acute care.
- BPCI Advanced: Continued the bundled payment approach on a voluntary basis, using retrospective payments that span acute and post-acute settings.
- CJR: Established a mandatory episode model for joint replacements, with savings driven largely by reductions in post-acute care spending.
- TEAM: Builds on prior joint replacement and episode-payment frameworks through a mandatory, multi-year model that expands bundled accountability for selected surgical procedures.
has announced more than 100 alternative payment and service delivery models and launched over 40 distinct payment models since its creation. These initiatives are active or time-limited experiments designed to test different approaches to care delivery, reimbursement, and provider accountability. https://youtu.be/juE4Q8AHBAk?si=8kNcEvGogIhakZLa
CMS Innovation Center Model Focus Areas
- Accountable care: Supports coordinated provider networks that share financial accountability for quality and cost outcomes.
- Episode-based payment: Focuses on defined clinical episodes or procedures, such as joint replacements.
- Primary care transformation: Strengthens primary care delivery through models such as advanced primary care practices and medical homes.
- Medicaid and CHIP: Tests state-level and targeted models for children, low-income populations, and other Medicaid or CHIP beneficiaries.
CMS does not maintain a separate Innovation Center category dedicated solely to post-acute care (PAC). Instead, post-acute reimbursement is generally incorporated into broader episode-based payment initiatives, including the Bundled Payments for Care Improvement (BPCI) initiative, Comprehensive Care for Joint Replacement (CJR), and the Transforming Episode Accountability Model (TEAM). Historically, the major pilot structures that directly targeted or substantially incorporated post-acute episodes include BPCI Models 2 and 3, BPCI Advanced, CJR, and TEAM.
Episode Models Involving Post-Acute Care
- BPCI Classic: Tested four models, including Model 2, which covered acute and post-acute care, and Model 3, which focused specifically on post-acute care.
- BPCI Advanced: Continued the bundled payment approach on a voluntary basis, using retrospective payments that span acute and post-acute settings.
- CJR: Established a mandatory episode model for joint replacements, with savings driven largely by reductions in post-acute care spending.
- TEAM: Builds on prior joint replacement and episode-payment frameworks through a mandatory, multi-year model that expands bundled accountability for selected surgical procedures.
Why Fee-for-Service Is Not Disappearing
Fee-for-service remains the operating foundation of much of American healthcare. It is administratively familiar, supports access in fragmented markets, and gives providers a direct line between services rendered and revenue received. It is also difficult to replace where data are incomplete, provider networks are thin, or outcomes are heavily influenced by factors outside a clinician’s control.
But fee-for-service is becoming less sufficient as a standalone model. Medicare and Medicare Advantage plans cannot manage long-term spending simply by adjusting unit payments every year. Payment reductions may protect a public budget in the short term, but they can also destabilize providers, reduce capacity, and shift costs elsewhere in the care continuum.
The practical direction is not a wholesale abandonment of fee-for-service. It is a layering of accountability on top of it. Providers will continue to bill for defined services, while a growing share of revenue and margin will depend on quality measures, total cost of care, utilization patterns, readmissions, patient experience, and performance against a target population.
That distinction matters. A skilled nursing facility may still receive a per-diem payment. A home health agency may still operate under episodic payment. Yet both will increasingly feel the financial consequences of avoidable hospitalization, poor transitions, inadequate documentation, and weak coordination with physicians, hospitals, and Medicare Advantage plans.
The Future of Healthcare Reimbursement Models Is Hybrid
The most likely future is a hybrid reimbursement environment rather than a clean conversion to capitation. Different patient populations, provider types, and markets require different levels of risk transfer.
For relatively predictable populations, especially those with chronic conditions and stable primary care relationships, population-based payment can create meaningful incentives for prevention, medication management, and early intervention. Accountable care organizations and advanced primary care models point in this direction. The provider has a reason to invest before a patient reaches the emergency department.
For high-acuity, episodic care, bundled payments will remain attractive because they create a defined period of accountability. Joint replacement bundles offered an early proof point. Post-acute care bundles are more complicated, but the logic is clear: hospitals and downstream providers should have aligned incentives around discharge planning, functional recovery, and preventing avoidable returns to the hospital.
For services where patient acuity is difficult to standardize or where access is fragile, prospective payment with carefully designed adjustments will remain essential. Hospice, skilled nursing, rural health, behavioral health, and complex home-based care cannot be managed responsibly through simplistic risk arrangements. A payment model that fails to account for clinical and social complexity does not create value. It creates selection pressure.
This is where policymakers and payors often get the design wrong. They treat downside risk as evidence of sophistication. It is not. Risk is useful only when the party accepting it has the information, care-management tools, network influence, and capital needed to manage it. Otherwise, risk is merely reimbursement reduction with a different label.
Risk Adjustment Will Become a Central Battleground
As payment moves toward outcomes and total cost, risk adjustment becomes more consequential. Providers serving medically complex, economically disadvantaged, rural, or behaviorally challenged populations must not be penalized for caring for patients others avoid.
Yet risk adjustment also invites scrutiny. Medicare Advantage has already demonstrated how aggressively coding intensity can affect public spending and plan economics. The policy challenge is to recognize legitimate clinical complexity without allowing documentation practices to become a revenue engine detached from patient need.
Operators should expect more validation, more audit exposure, and greater pressure to reconcile assessment data, clinical records, claims, and quality reporting. Documentation will no longer be viewed as a back-office compliance obligation. It will be part of the organization’s reimbursement strategy and risk-control system.
Medicare Advantage Will Shape Provider Economics
No discussion of reimbursement can ignore Medicare Advantage. In many markets, Medicare Advantage enrollment has changed the center of gravity in post-acute contracting. Providers increasingly negotiate not only with traditional Medicare rules in mind, but with plan-specific networks, prior authorization requirements, payment rates, and utilization management practices.
This shift creates real opportunities for organizations that can demonstrate preferred-provider performance. A high-performing skilled nursing operator, home health agency, or physician group can use lower readmissions, shorter but appropriate lengths of stay, and reliable patient outcomes to earn network relevance. But network relevance is not the same as negotiating leverage. In concentrated insurance markets, plans retain substantial power over rates and authorization terms.
The strategic danger is becoming dependent on managed care volume while lacking visibility into the true economics of that volume. A full census does not compensate for contracts that underpay clinical intensity, delay authorization, or push financial risk downstream without adequate protection.
Executives should evaluate managed care relationships at the contract, service-line, and patient-acuity level. Average revenue per day or per episode is not enough. The organization needs to understand administrative burden, denial patterns, length-of-stay constraints, staffing demands, and the cost of caring for patients whose needs exceed the assumptions built into the rate.
Data Capability Will Separate Winners From Participants
The next generation of reimbursement will reward organizations that can turn data into operating decisions. That does not mean every provider needs an elaborate technology stack or a large analytics department. It does mean leadership must know where margin is created and destroyed.
A provider entering a value-based arrangement should be able to identify its high-risk patients, measure avoidable utilization, track referral-source performance, and compare outcomes by payor. It should know whether its workforce model supports the quality commitments embedded in its contracts. It should also know which care transitions repeatedly fail and why.
Many organizations still treat quality data, finance data, and clinical data as separate management systems. That approach is increasingly untenable. A rise in falls, medication errors, unplanned transfers, or staff turnover is not simply a clinical or human resources issue. It has direct implications for reimbursement, contract performance, survey risk, and enterprise value.
The strongest operators will build a common operating language across clinical, financial, and contracting teams. They will use data to challenge assumptions before a payor, regulator, or investor does it for them.
The Trade-Off: Incentives Can Improve Care or Restrict It
Value-based reimbursement has a compelling policy case. Paying for better outcomes rather than more services is a sensible objective. But payment design can create perverse incentives if safeguards are weak.
An organization under pressure to reduce total cost may avoid high-need patients, limit services that are clinically appropriate, or transfer patients prematurely. A plan focused narrowly on utilization may turn prior authorization into a barrier rather than a clinical-management tool. A provider facing penalties for readmissions may become reluctant to send a deteriorating patient to the hospital when escalation is warranted.
That is why quality measurement must move beyond easily counted process measures. Functional improvement, patient goals, caregiver burden, access, timely treatment, and equity all matter. They are harder to measure, but they reflect the reality of caring for older adults and medically complex populations.
Federal policy should also recognize that providers cannot be expected to absorb every social failure through reimbursement risk. Housing instability, food insecurity, transportation gaps, and caregiver exhaustion materially affect outcomes. Holding providers accountable for these factors without supporting community infrastructure is not value-based care. It is cost shifting.
What Leaders Should Do Now
Healthcare leaders do not need to predict every CMS rule or Medicare Advantage contract change. They do need to prepare for a payment environment in which performance variation is more visible and less easily hidden by aggregate volume.
Start by identifying which service lines are most exposed to value-based contracting and which payors hold the greatest leverage. Then assess whether current clinical and financial systems can measure performance at the level where risk is actually being assigned. If an organization cannot explain its cost and outcomes by population, referral source, payor, and acuity, it is not ready to price risk intelligently.
Just as important, resist the temptation to sign risk-based contracts for the appearance of strategic progress. Some arrangements offer legitimate upside and a stronger market position. Others transfer volatility to providers that lack the scale or infrastructure to manage it. The distinction is found in the details: attribution, risk adjustment, exclusions, quality definitions, data access, stop-loss provisions, and dispute resolution.
The organizations best positioned for the next reimbursement cycle will not be those that simply chase value-based care. They will be those that can prove what value costs, what it requires operationally, and where the limits of financial accountability should be drawn.
